BlackRock Advisors’s Insight Molecular Diagnostics IMDX Stock Holding History

BlackRock Advisors’s Portfolio IMDX Stock Details IMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$3K	Hold	24	–	–	﹤0.01%	3660
2016 Q3	$2K	Hold	24	–	–	﹤0.01%	3686
2016 Q2	$2K	Sell	24 -40	-63%	-$3.74K	﹤0.01%	3716
2016 Q1	$6K	Buy	+64	New	+$5.67K	﹤0.01%	3650

Other funds holding IMDX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MHP

Manatuck Hill Partners Westport, Connecticut $302M AUM 117.41% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

DWM

Destination Wealth Management Walnut Creek, California $4.28B AUM 19.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Family Management New York $975M AUM 23.16% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BlackRock Advisors's IMDX Position: Q4 2016 in Review

BlackRock Advisors held its Insight Molecular Diagnostics (IMDX) position steady in Q4 2016 at 24 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #3660.

BlackRock Advisors first reported a position in IMDX in Q1 2016 and has held it in 4 quarters since. The position peaked at $6K in Q1 2016. 32 funds tracked by Wall St. Rank hold IMDX as of Q4 2016.

BlackRock Advisors held 24 shares of Insight Molecular Diagnostics worth $3K as of Q4 2016.
BlackRock Advisors left its Insight Molecular Diagnostics share count unchanged in Q4 2016.
Insight Molecular Diagnostics made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #3660 holding.
BlackRock Advisors first reported a position in Insight Molecular Diagnostics in Q1 2016 and has held it in 4 quarters since.
BlackRock Advisors's Insight Molecular Diagnostics position peaked at $6K in Q1 2016.
32 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.